Up-and-coming biotech player Mesoblast [ASX:MSB] is on the up today. The regenerative medicine company announced some promising results from a Phase III drug trial from data that was shared at the American Heart Association’s annual ‘Scientific Sessions’, an exhibition of the latest findings and insights into all things heart health related.
ASX:MSB Chart by TradingView
Mesoblast Ltd (ASX:MSB) Company Information
Mesoblast Ltd (ASX:MSB) Financial Information
ASX:MSB Fundamental Data / Rates by TradingView
Mesoblast Ltd (ASX:MSB) Latest News & Updates
The MSB share price down 14%. The Mesoblast [ASX:MSB] posted a FY21 net loss of $98.8 million as the FDA asks for further trials of MSB’s emergency COVID treatment...